Assembly Biosciences Announces October Conference Participation
October 05 2020 - 7:30AM
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage
biotechnology company developing innovative therapeutics targeting
hepatitis B virus (HBV) and diseases associated with the
microbiome, announced participation in two upcoming conferences
focused on HBV.
ICE-HBV Serum Biomarkers Virtual Workshop
2020Panel: What are the virological and
immunological gaps that need to be addressed? What biomarkers are
most needed to meet HBV cure endpoints?Panelist:
William Delaney, PhD, Chief Scientific Officer,
VirologyDate/Time: Monday, October 5, 2020 at
9:35am ET
H.C.
Wainwright HBV
Mini-Conference -
VirtualPresenter: John McHutchison, AO, MD, Chief
Executive Officer and PresidentDate/Time: Tuesday,
October 20, 2020 at 10:30am ET
A webcast of the HBV Mini-Conference will be available in the
Events and Presentations section of the Company’s website at
www.assemblybio.com.
About HBVChronic hepatitis B virus (HBV)
infection is a debilitating disease of the liver that afflicts over
250 million people worldwide with up to 90 million people in China,
as estimated by the World Health Organization. HBV is a global
epidemic that affects more people than hepatitis C virus (HCV) and
HIV infection combined—with a higher morbidity and mortality rate.
HBV is a leading cause of chronic liver disease and need for liver
transplantation, and up to one million people worldwide die every
year from HBV-related causes.
The current standard of care for patients with chronic HBV
infection is life-long suppressive treatment with medications that
reduce, but do not eliminate, the virus, resulting in very low cure
rates. There is a significant unmet need for new therapies to treat
HBV.
About Assembly BiosciencesAssembly Biosciences,
Inc. is a clinical-stage biotechnology company developing
innovative therapeutics targeting hepatitis B virus (HBV) and
diseases associated with the microbiome. The HBV program is focused
on advancing a new class of potent, oral core inhibitors that have
the potential to increase cure rates for chronically infected
patients. The microbiome program is developing novel oral live
microbial biotherapeutic candidates with Assembly’s fully
integrated platform, including a robust process for strain
identification and selection, GMP manufacturing expertise and
targeted delivery to the lower gastrointestinal tract with the
GEMICEL® technology. For more information, visit
assemblybio.com.
ContactsAssembly Biosciences, Inc.Lauren
GlaserSenior Vice President, Investor Relations and Corporate
Affairs(415) 521-3828lglaser@assemblybio.com
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Sep 2023 to Sep 2024